Clinical implications of the insulin resistance syndrome

Clinical Cornerstone

Volumn 1, Issue 3, 1998, Pages 13-26

  Garvey, W Timothy ^a,b   Hermayer, Kathie L ^c  

^a Department of Medicine ^*  (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN;

ALBUMINURIA; BLOOD; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; HUMAN; HYPERINSULINISM; HYPERLIPIDEMIA; HYPERTENSION; INSULIN RESISTANCE; METABOLISM; OBESITY; PRACTICE GUIDELINE; REVIEW; SYNDROME;

ALBUMINURIA; BLOOD GLUCOSE; GLUCOSE INTOLERANCE; HUMANS; HYPERINSULINISM; HYPERLIPIDEMIAS; HYPERTENSION; INSULIN; INSULIN RESISTANCE; OBESITY; PRACTICE GUIDELINES; SYNDROME;

EID: 0032222862     PISSN: 10983597     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1098-3597(98)90015-1     Document Type: Article

References (21)

1. Reaven GM. Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37: 1595-1607.
2. Schade DS, Boyle PJ. Insulin resistance: its role in health and disease. Clin Diab. 1992:10(1):3-6.
3. Hunter SJ, Garvey WT. Insulin action and insulin resistance: diseases involving defects in insulin receptors, signal transduction, and the glucose transport effector system. Am J Med. 1998. In press.
4. Krenz AJ. Insulin resistance. BMJ. 1996;313: 1385-1389.
5. Nestler J, Jakubowicz DJ. Decreases in ovarian cytochrome P450c17α activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. NEJM. 1996;335(9): 617-623.
6. Ehrmann DA, Schneider DJ, Sobel BE, et al. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1997;82(7):2108-2116.
7. American Diabetes Association. Consensus development conference on insulin resistance. Diabetes Care. 1998;21(2):310-314.
8. Groop LC, Tuomi T. Non-insulin-dependent diabetes mellitus - a collision between thrifty genes and an affluent society. Ann Med. 1997;29:37-53.
9. Stern MP. Diabetes and cardiovascular disease. "The Common Soil Hypothesis." Diabetes. 1995; 44:369-374.
10. Despres JP, Lamarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. NEJM. 1996;334:952-957.
11. Meigs JB, Nathan DM, Wilson PW, et al. Metabolic risk factors worsen continuously across the spectrum of nondiabetic glucose tolerance: The Framingham Offspring Study. Ann Intern Med. 1998;128: 524-533.
12. Kissebah AH, Vydelingum N, Murray R, et al. Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab. 1982;54(2):254-260.
13. Shamiss A, Carroll J, Rosenthal T. Insulin resistance in secondary hypertension. Am J Hypertens. 1992;5: 26-28.
14. Jensen MD, Haymond MW, Rizza RA, et al. Influence of body fat distribution on free fatty acid metabolism in obesity. J Clin Invest. 1989;83:1168-1173.
15. Robbins DC, Anderson L, Bowsher R, et al. Report of the American Diabetes Association's task force on standardization of the insulin assay. Diabetes. 1996; 45:242-256.
16. Henry RR, Wallace P, Olefsky JM. Effects of weight loss on mechanisms of hyperglycemia in obese non-insulin-dependent diabetes mellitus. Diabetes. 1986;35:990-998.
17. Mayer-Davis EJ, D'Agostino R, Karter AJ, et al. Intensity and amount of physical activity in relation to insulin sensitivity. JAMA. 1998;279(9):669-674.
18. Tenkanen L, Manttari M, Manninen V. Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki Heart Study. Circulation. 1995;92(7): 1779-1785.
19. Blankenhorn DH, Nessim SA, Johnson RL, et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987;257:3233-3240.
20. American Diabetes Association. Aspirin therapy in diabetes mellitus [technical review]. Diabetes Care. 1997;20:1767-1771.
21. Welch GN, Loscalzo J. Homocysteine and atherosclerosis. NEJM. 1998;338(15): 1042-1050.